Deyan Yordanov Yosifov

11PUBLICATIONS
55CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jun 20, 2026
Ibrutinib for early-stage CLL: genetic risk factors and treatment outcome in the GCLLSG CLL12 trial.

|Jun 17, 2026
IGLV3-21R110 and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL.

|Jun 09, 2026
PLCG2 exon-skipped variants: insights into their potential role in chronic lymphocytic leukemia.

|Jun 02, 2025
NOTCH1 signaling is dysregulated by loss of the deubiquitinase USP28 with del(11q), uncovering USP28 inhibition as novel therapeutic target in CLL.

Alena Sophie Ehrmann, Miguel Quijada-Álamo, Viola Close

|Apr 29, 2024
T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia.

Philipp M Roessner, Isabelle Seufert, Vicente Chapaprieta

|May 03, 2020
DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy.

Deyan Yordanov Yosifov, Johannes Bloehdorn, Hartmut Döhner

Pageof 2

Frequent Collaborators

5 joint publications

Daniel Mertens

2 joint publications

Marc Zapatka

2 joint publications

Peter Gierschik

2 joint publications

Sascha Endres